about
The emerging role of histone lysine demethylases in prostate cancerCytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Clinical significance of Polycomb gene expression in brain tumors.Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role.Polycomb-mediated silencing in neuroendocrine prostate cancer.Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerMutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alterationPharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.Targeting prostate cancer stem cells.Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerOptical biosensors to analyze novel biomarkers in oncology.Cancer stem cell epigenetics and chemoresistance.Histone modifications, stem cells and prostate cancer.The epigenetic/noncoding origin of tumor dormancy.The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo.A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.The potential role of PHF6 as an oncogene: a genotranscriptomic/proteomic meta-analysis.miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer.Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validationIdentification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.Histone code, human growth and cancerElevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.Heterochromatin protein 1α mediates development and aggressiveness of neuroendocrine prostate cancer.Induced pluripotent stem cells derived from liver disease patients can differentiate into functional hepatocytes.Biological significance of DNA methylation patterns in human progenitor cells.The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzleThe long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional programEZH2 and cancer stem cells: fact or fiction?Transfection of a methylated promoter drives mesenchymal stem cell differentiationPrognostic value of CD133 caused by mutant K-Ras and B-Raf--letterFaithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?Embryonic stem cell pathways and chemotherapy response: an unexplored routeGenome-epigenome interactions: the Polycomb paradoxAre there any HOTTIPs for defining coding potential of lncRNAs, or just a lot of HOTAIR?Hypoxia and Noncoding RNAs in Taxane Resistance
P50
Q21245762-DC5BAD1A-E5BF-4410-918E-3686F68B9BE7Q33704464-FDA06176-157D-4935-95FE-A35CDE071300Q34221286-6946AE8F-07A6-4AE0-9D8E-34EC575A4E65Q34354646-0EC471AE-F8C7-43E0-820F-39CC3EAFDBA8Q35336915-85919ABA-C3C2-4E1D-8544-0F1899BE3EE8Q35836756-DD26FF52-29AE-486F-BBBC-680D633F7880Q36574886-90DF9213-8240-4050-A733-AEC3BBDE8932Q37182184-8574925B-302B-4BA0-92F3-E840DB0DA792Q37359139-68A7E024-DE37-42A0-A942-6A5739FBF5B0Q37635203-9AF42BF7-50A8-46A0-B910-250390272879Q37718438-C2356471-7C19-4B66-8222-4F104CF211AEQ37875029-CAD26406-9A36-479E-A224-546FF8BE9FA7Q37961977-500C93E1-DF75-461F-AB15-D831F6C1CDCDQ38124333-4579E649-B795-4789-98E7-1F3C92D4FE70Q38900059-2AFF96D9-5E36-4AE9-A4BC-5EB486AB570AQ38903008-DA470ADE-E34F-48EC-9995-7E420F3065C7Q39322941-7136F996-9226-4981-B657-3CC033F3DD03Q40329193-F10FC766-9969-4A31-959E-9C4A1962C1D6Q41064068-29620238-DFE6-4A38-A6B1-A776DC4D948BQ41346071-D3C10516-66E1-42FD-AF83-D887004CE0D2Q41533087-D64E4703-4E87-4A2C-ABB0-7370E02F8CAFQ41830742-F4D7D81C-E0C5-4ED2-91F6-439E227C1717Q42282866-E9DC52F8-70D7-41A6-94A1-62CEC0A8496BQ42609221-38032DF1-00B1-4DAB-80A5-004A70461D4FQ42688119-12AC0DA3-749A-41BD-92BF-79D57C2DC513Q51541898-079326CF-1A3D-4632-BF66-1AAA13D2B093Q52682476-642C10BC-C01C-4C16-81D6-AA5AE9F55686Q53193231-1779080B-6E55-457D-8DBE-1F9AB4480908Q53193232-7DBCA79D-62DE-4727-ADF4-ABCA4B6C7DC8Q53789333-F22C1EDF-0E89-4ABA-83F0-EB3D7E652AF0Q62976255-4E0427E1-508B-4CB4-98E8-91FC3574AB1FQ64064101-51D13400-11FD-44C4-86EC-B75232CBB9D0Q82704040-D6EE029C-6B52-42B5-9E9B-33F7E7D2F104Q82725415-AF571F70-93F6-4744-AA18-5370627E7CBBQ84587772-2AEDDC8B-01F8-4501-9C16-8B13A6AC6351Q84592693-5E96DDC0-C9B2-4E0C-B99C-2589D755B813Q85646687-BE255C5A-5CBE-443F-BAA5-8F52DC55F404Q87378857-231BD990-6AB9-42CB-9759-1E521E08A875Q88616947-D4D936CA-9356-40E8-BAAC-9AD64438DE06Q89067672-0B002BFC-F3E4-4407-A984-7C58504DB1FC
P50
description
researcher ORCID ID = 0000-0002-4903-2973
@en
wetenschapper
@nl
name
Francesco Crea
@ast
Francesco Crea
@en
Francesco Crea
@es
Francesco Crea
@nl
type
label
Francesco Crea
@ast
Francesco Crea
@en
Francesco Crea
@es
Francesco Crea
@nl
prefLabel
Francesco Crea
@ast
Francesco Crea
@en
Francesco Crea
@es
Francesco Crea
@nl
P106
P21
P31
P496
0000-0002-4903-2973